• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
SNT 6.67% 4.2¢

SYNTARA LIMITED - Announcements

Syntara Limited is an Australia-based clinical-stage drug development company. The... Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk

Filters [Clear]
  • Price Sensitive: Yes
SNT Quarterly Activities ReportPRICE SENSITIVE30/10/24 download Created with Sketch. 141.52KB
SNT Quarterly Appendix 4C Cash Flow ReportPRICE SENSITIVE30/10/24 download Created with Sketch. 225.53KB
SNT Appendix 4E and Annual Report to shareholdersPRICE SENSITIVE30/08/24 download Created with Sketch. 1.81MB
SNT Quarterly Activities ReportPRICE SENSITIVE30/07/24 download Created with Sketch. 208.21KB
SNT Quarterly Appendix 4C Cash Flow ReportPRICE SENSITIVE30/07/24 download Created with Sketch. 235KB
SNT Equity Raising PresentationPRICE SENSITIVE30/07/24 download Created with Sketch. 1.45MB
SNT PlacementPRICE SENSITIVE30/07/24 download Created with Sketch. 129.81KB
SNT Trading HaltPRICE SENSITIVE29/07/24 download Created with Sketch. 546.62KB
SNT Quarterly Activities ReportPRICE SENSITIVE30/04/24 download Created with Sketch. 201.7KB
SNT Quarterly Activities/Appendix 4C Cash Flow ReportPRICE SENSITIVE30/04/24 download Created with Sketch. 234.71KB
SNT Half Yearly Report and AccountsPRICE SENSITIVE29/02/24 download Created with Sketch. 792.29KB
SNT Quarterly Activities ReportPRICE SENSITIVE31/01/24 download Created with Sketch. 343.15KB
SNT Quarterly Appendix 4C Cash Flow ReportPRICE SENSITIVE31/01/24 download Created with Sketch. 223.07KB
SNT PlacementPRICE SENSITIVE19/12/23 download Created with Sketch. 367.31KB
SNT Trading HaltPRICE SENSITIVE18/12/23 download Created with Sketch. 399.59KB
SNT Quarterly Activities ReportPRICE SENSITIVE31/10/23 download Created with Sketch. 818.62KB
SNT Quarterly Appendix 4C Cash Flow ReportPRICE SENSITIVE31/10/23 download Created with Sketch. 402.52KB
SNT PXS Company Restructure Sale of Mannitol BusinessPRICE SENSITIVE03/10/23 download Created with Sketch. 498.47KB
SNT Trading HaltPRICE SENSITIVE02/10/23 download Created with Sketch. 556.33KB
SNT Preliminary Final ReportPRICE SENSITIVE28/08/23 download Created with Sketch. 2.05MB
SNT PXS to Receive Prepayment of 2023 Research Tax IncentivePRICE SENSITIVE08/08/23 download Created with Sketch. 188.43KB
SNT Quarterly Activities ReportPRICE SENSITIVE31/07/23 download Created with Sketch. 643.63KB
SNT Quarterly Appendix 4C Cash Flow ReportPRICE SENSITIVE31/07/23 download Created with Sketch. 330.79KB
SNT Final Set of Interim Data from PXS-5505 in MyelofibrosisPRICE SENSITIVE12/07/23 download Created with Sketch. 245.37KB
SNT PXS Announces Encouraging Results from Phase 1c Scar StudyPRICE SENSITIVE23/05/23 download Created with Sketch. 235.37KB
SNT Trading HaltPRICE SENSITIVE22/05/23 download Created with Sketch. 369.47KB
SNT Quarterly Activities/Appendix 4C Cash Flow ReportPRICE SENSITIVE28/04/23 download Created with Sketch. 625.51KB
SNT Quarterly Activities/Appendix 4C Cash Flow ReportPRICE SENSITIVE28/04/23 download Created with Sketch. 323.77KB
SNT After FDA Review PXS Accelerates Plans for Combination StudyPRICE SENSITIVE12/04/23 download Created with Sketch. 223.25KB
SNT Half Yearly Report and AccountsPRICE SENSITIVE10/02/23 download Created with Sketch. 718.73KB
SNT Quarterly Activities ReportPRICE SENSITIVE31/01/23 download Created with Sketch. 529.73KB
SNT Quarterly Activities/Appendix 4C Cash Flow ReportPRICE SENSITIVE31/01/23 download Created with Sketch. 219.35KB
SNT Quarterly Activities ReportPRICE SENSITIVE31/10/22 download Created with Sketch. 869.62KB
SNT Quarterly Activities/Appendix 4C Cash Flow ReportPRICE SENSITIVE31/10/22 download Created with Sketch. 219.1KB
SNT PXS announces positive interim data from myelofibrosis trialPRICE SENSITIVE19/10/22 download Created with Sketch. 257.53KB
SNT Investor PresentationPRICE SENSITIVE19/10/22 download Created with Sketch. 1.56MB
SNT PlacementPRICE SENSITIVE19/10/22 download Created with Sketch. 223.88KB
SNT Trading HaltPRICE SENSITIVE18/10/22 download Created with Sketch. 372.8KB
SNT PXS Releases Promising Interim Data from Skin Scarring StudyPRICE SENSITIVE26/09/22 download Created with Sketch. 182.78KB
SNT PXS to Receive Stg2.9m from Parkinsons UK for New TrialPRICE SENSITIVE01/09/22 download Created with Sketch. 208.6KB
SNT Preliminary Final ReportPRICE SENSITIVE30/08/22 download Created with Sketch. 859.7KB
SNT Aptar Pharma Pays PXS Us$5m to Acquire Orbital TechnologyPRICE SENSITIVE04/08/22 download Created with Sketch. 167.45KB
SNT Quarterly Activities/Appendix 4C Cash Flow ReportPRICE SENSITIVE29/07/22 download Created with Sketch. 471.83KB
SNT Quarterly Appendix 4C Cash Flow ReportPRICE SENSITIVE29/07/22 download Created with Sketch. 199.5KB
SNT Clarification AnnouncementPRICE SENSITIVE13/05/22 download Created with Sketch. 305.36KB
SNT Quarterly Activities ReportPRICE SENSITIVE29/04/22 download Created with Sketch. 496.87KB
SNT Appendix 4C Quarterly Cash Flow ReportPRICE SENSITIVE29/04/22 download Created with Sketch. 193.55KB
SNT Half Yearly Report and AccountsPRICE SENSITIVE11/02/22 download Created with Sketch. 402.94KB
SNT Quarterly Activities ReportPRICE SENSITIVE31/01/22 download Created with Sketch. 529.16KB
SNT Quarterly Appendix 4C Cash Flow ReportPRICE SENSITIVE31/01/22 download Created with Sketch. 193.78KB
SNT Response to ASX Aware QueryPRICE SENSITIVE10/01/22 download Created with Sketch. 392.67KB
SNT PXS Collaborators Receive Government Grants of $1.4mPRICE SENSITIVE06/01/22 download Created with Sketch. 156.38KB
SNT Share Purchase PlanPRICE SENSITIVE20/12/21 download Created with Sketch. 145.24KB
SNT Security Purchase PlanPRICE SENSITIVE25/11/21 download Created with Sketch. 389.6KB
SNT Investor PresentationPRICE SENSITIVE17/11/21 download Created with Sketch. 2.22MB
SNT PlacementPRICE SENSITIVE17/11/21 download Created with Sketch. 152.6KB
SNT Trading HaltPRICE SENSITIVE15/11/21 download Created with Sketch. 228.42KB
SNT FDA Clears PXS Cancer Drug for Phase 2 Liver Cancer StudyPRICE SENSITIVE09/11/21 download Created with Sketch. 118.69KB
SNT Quarterly Activities ReportPRICE SENSITIVE28/10/21 download Created with Sketch. 514.55KB
SNT Appendix 4C Cash Flow ReportPRICE SENSITIVE28/10/21 download Created with Sketch. 193.16KB
SNT PXS Doses First Patient in Phase 2 Bone Marrow Cancer TrialPRICE SENSITIVE13/10/21 download Created with Sketch. 116.37KB
SNT PXS Cleared to Progress to Phase 2 Bone Marrow Cancer TrialPRICE SENSITIVE05/10/21 download Created with Sketch. 165.64KB
SNT Pharmaxis Treatment to Prevent Wound and Burns Scars ClearsPRICE SENSITIVE31/08/21 download Created with Sketch. 133.42KB
SNT PXS Grants Exclusive Option to Develop High Payload InhalerPRICE SENSITIVE17/08/21 download Created with Sketch. 169.14KB
SNT Preliminary Final ReportPRICE SENSITIVE12/08/21 download Created with Sketch. 945.3KB
SNT PXS Drug Decreases Tumour Burden in Liver Cancer ModelPRICE SENSITIVE05/08/21 download Created with Sketch. 132.32KB
SNT Quarterly Activities/Appendix 4C Cash Flow ReportPRICE SENSITIVE28/07/21 download Created with Sketch. 1.13MB
SNT Quarterly Activities/Appendix 4C Cash Flow ReportPRICE SENSITIVE28/07/21 download Created with Sketch. 180KB
SNT PXS Sells Australian Distribution Rights for A$2mPRICE SENSITIVE01/07/21 download Created with Sketch. 146.07KB
SNT BTC: Exclusive distribution rights for Bronchitol & AridolPRICE SENSITIVE30/06/21 download Created with Sketch. 118.62KB
SNT PXS Announces First Results in Bone Marrow Cancer TrialPRICE SENSITIVE29/06/21 download Created with Sketch. 118.64KB
SNT Quarterly Activity ReportPRICE SENSITIVE30/04/21 download Created with Sketch. 498KB
SNT Appendix 4C - quarterlyPRICE SENSITIVE30/04/21 download Created with Sketch. 179.97KB
SNT Sale of Russian Distribution RightsPRICE SENSITIVE14/04/21 download Created with Sketch. 144.32KB
SNT Investor Presentation Capital Raising and Growth OutlookPRICE SENSITIVE14/04/21 download Created with Sketch. 2.45MB
SNT PlacementPRICE SENSITIVE14/04/21 download Created with Sketch. 146.13KB
SNT Trading HaltPRICE SENSITIVE13/04/21 download Created with Sketch. 218.32KB
SNT First Patient Enrolled - Clinical Trial for Cancer TreatmentPRICE SENSITIVE22/02/21 download Created with Sketch. 132.47KB
SNT Half Yearly Report and AccountsPRICE SENSITIVE10/02/21 download Created with Sketch. 430.36KB
SNT Pharmaxis Exports CF Drug to US - US$3 Million MilestonePRICE SENSITIVE09/02/21 download Created with Sketch. 101.56KB
SNT Appendix 4C - quarterlyPRICE SENSITIVE29/01/21 download Created with Sketch. 180.59KB
SNT Quarterly Activity Report - December 2020PRICE SENSITIVE29/01/21 download Created with Sketch. 488.55KB
SNT Pharmaxis Receives US$7m milestone from ChiesiPRICE SENSITIVE29/12/20 download Created with Sketch. 96.51KB
SNT Pharmaxis Prioritises Clinical Program on MyelofibrosisPRICE SENSITIVE02/11/20 download Created with Sketch. 136.14KB
SNT FDA Approves Bronchitol for US MarketPRICE SENSITIVE02/11/20 download Created with Sketch. 133.59KB
SNT Appendix 4C - quarterlyPRICE SENSITIVE30/10/20 download Created with Sketch. 181.37KB
SNT September Quarter 2020 Activity ReportPRICE SENSITIVE30/10/20 download Created with Sketch. 364.14KB
SNT Boehringer Ingelheim discontinues development of BI 1467335PRICE SENSITIVE07/09/20 download Created with Sketch. 684.06KB
SNT Pharmaxis Awarded $1M Australian Government GrantPRICE SENSITIVE03/09/20 download Created with Sketch. 123.9KB
SNT FDA Gives Green Light to Start Myelofibrosis Phase 2 StudyPRICE SENSITIVE19/08/20 download Created with Sketch. 91.4KB
SNT Preliminary Final ReportPRICE SENSITIVE13/08/20 download Created with Sketch. 934.75KB
SNT US$7 million Bronchitol Launch Milestone Brought ForwardPRICE SENSITIVE05/08/20 download Created with Sketch. 101.07KB
SNT Fourth Quarter Activity ReportPRICE SENSITIVE31/07/20 download Created with Sketch. 385.4KB
SNT Appendix 4C - quarterlyPRICE SENSITIVE31/07/20 download Created with Sketch. 173.02KB
SNT Appendix 4C - quarterlyPRICE SENSITIVE30/04/20 download Created with Sketch. 88.08KB
SNT Pharmaxis Quarterly Shareholder Update - March 2020PRICE SENSITIVE30/04/20 download Created with Sketch. 392.68KB
SNT PXS Cancer Drug Ready to Commence Phase 2 Studies Q4 2020PRICE SENSITIVE28/04/20 download Created with Sketch. 145.17KB
SNT Half Yearly Report and AccountsPRICE SENSITIVE13/02/20 download Created with Sketch. 251.24KB
SNT Appendix 4C - quarterlyPRICE SENSITIVE31/01/20 download Created with Sketch. 121.39KB
SNT Quarterly Shareholder Update - December 2019PRICE SENSITIVE31/01/20 download Created with Sketch. 372.47KB
SNT Quarterly Activities Report
30/10/24PRICE SENSITIVE download Created with Sketch. 141.52KB
SNT Quarterly Appendix 4C Cash Flow Report
30/10/24PRICE SENSITIVE download Created with Sketch. 225.53KB
SNT Appendix 4E and Annual Report to shareholders
30/08/24PRICE SENSITIVE download Created with Sketch. 1.81MB
SNT Quarterly Activities Report
30/07/24PRICE SENSITIVE download Created with Sketch. 208.21KB
SNT Quarterly Appendix 4C Cash Flow Report
30/07/24PRICE SENSITIVE download Created with Sketch. 235KB
SNT Equity Raising Presentation
30/07/24PRICE SENSITIVE download Created with Sketch. 1.45MB
SNT Placement
30/07/24PRICE SENSITIVE download Created with Sketch. 129.81KB
SNT Trading Halt
29/07/24PRICE SENSITIVE download Created with Sketch. 546.62KB
SNT Quarterly Activities Report
30/04/24PRICE SENSITIVE download Created with Sketch. 201.7KB
SNT Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24PRICE SENSITIVE download Created with Sketch. 234.71KB
SNT Half Yearly Report and Accounts
29/02/24PRICE SENSITIVE download Created with Sketch. 792.29KB
SNT Quarterly Activities Report
31/01/24PRICE SENSITIVE download Created with Sketch. 343.15KB
SNT Quarterly Appendix 4C Cash Flow Report
31/01/24PRICE SENSITIVE download Created with Sketch. 223.07KB
SNT Placement
19/12/23PRICE SENSITIVE download Created with Sketch. 367.31KB
SNT Trading Halt
18/12/23PRICE SENSITIVE download Created with Sketch. 399.59KB
SNT Quarterly Activities Report
31/10/23PRICE SENSITIVE download Created with Sketch. 818.62KB
SNT Quarterly Appendix 4C Cash Flow Report
31/10/23PRICE SENSITIVE download Created with Sketch. 402.52KB
SNT PXS Company Restructure Sale of Mannitol Business
03/10/23PRICE SENSITIVE download Created with Sketch. 498.47KB
SNT Trading Halt
02/10/23PRICE SENSITIVE download Created with Sketch. 556.33KB
SNT Preliminary Final Report
28/08/23PRICE SENSITIVE download Created with Sketch. 2.05MB
SNT PXS to Receive Prepayment of 2023 Research Tax Incentive
08/08/23PRICE SENSITIVE download Created with Sketch. 188.43KB
SNT Quarterly Activities Report
31/07/23PRICE SENSITIVE download Created with Sketch. 643.63KB
SNT Quarterly Appendix 4C Cash Flow Report
31/07/23PRICE SENSITIVE download Created with Sketch. 330.79KB
SNT Final Set of Interim Data from PXS-5505 in Myelofibrosis
12/07/23PRICE SENSITIVE download Created with Sketch. 245.37KB
SNT PXS Announces Encouraging Results from Phase 1c Scar Study
23/05/23PRICE SENSITIVE download Created with Sketch. 235.37KB
SNT Trading Halt
22/05/23PRICE SENSITIVE download Created with Sketch. 369.47KB
SNT Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23PRICE SENSITIVE download Created with Sketch. 625.51KB
SNT Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23PRICE SENSITIVE download Created with Sketch. 323.77KB
SNT After FDA Review PXS Accelerates Plans for Combination Study
12/04/23PRICE SENSITIVE download Created with Sketch. 223.25KB
SNT Half Yearly Report and Accounts
10/02/23PRICE SENSITIVE download Created with Sketch. 718.73KB
SNT Quarterly Activities Report
31/01/23PRICE SENSITIVE download Created with Sketch. 529.73KB
SNT Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23PRICE SENSITIVE download Created with Sketch. 219.35KB
SNT Quarterly Activities Report
31/10/22PRICE SENSITIVE download Created with Sketch. 869.62KB
SNT Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22PRICE SENSITIVE download Created with Sketch. 219.1KB
SNT PXS announces positive interim data from myelofibrosis trial
19/10/22PRICE SENSITIVE download Created with Sketch. 257.53KB
SNT Investor Presentation
19/10/22PRICE SENSITIVE download Created with Sketch. 1.56MB
SNT Placement
19/10/22PRICE SENSITIVE download Created with Sketch. 223.88KB
SNT Trading Halt
18/10/22PRICE SENSITIVE download Created with Sketch. 372.8KB
SNT PXS Releases Promising Interim Data from Skin Scarring Study
26/09/22PRICE SENSITIVE download Created with Sketch. 182.78KB
SNT PXS to Receive Stg2.9m from Parkinsons UK for New Trial
01/09/22PRICE SENSITIVE download Created with Sketch. 208.6KB
SNT Preliminary Final Report
30/08/22PRICE SENSITIVE download Created with Sketch. 859.7KB
SNT Aptar Pharma Pays PXS Us$5m to Acquire Orbital Technology
04/08/22PRICE SENSITIVE download Created with Sketch. 167.45KB
SNT Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22PRICE SENSITIVE download Created with Sketch. 471.83KB
SNT Quarterly Appendix 4C Cash Flow Report
29/07/22PRICE SENSITIVE download Created with Sketch. 199.5KB
SNT Clarification Announcement
13/05/22PRICE SENSITIVE download Created with Sketch. 305.36KB
SNT Quarterly Activities Report
29/04/22PRICE SENSITIVE download Created with Sketch. 496.87KB
SNT Appendix 4C Quarterly Cash Flow Report
29/04/22PRICE SENSITIVE download Created with Sketch. 193.55KB
SNT Half Yearly Report and Accounts
11/02/22PRICE SENSITIVE download Created with Sketch. 402.94KB
SNT Quarterly Activities Report
31/01/22PRICE SENSITIVE download Created with Sketch. 529.16KB
SNT Quarterly Appendix 4C Cash Flow Report
31/01/22PRICE SENSITIVE download Created with Sketch. 193.78KB
SNT Response to ASX Aware Query
10/01/22PRICE SENSITIVE download Created with Sketch. 392.67KB
SNT PXS Collaborators Receive Government Grants of $1.4m
06/01/22PRICE SENSITIVE download Created with Sketch. 156.38KB
SNT Share Purchase Plan
20/12/21PRICE SENSITIVE download Created with Sketch. 145.24KB
SNT Security Purchase Plan
25/11/21PRICE SENSITIVE download Created with Sketch. 389.6KB
SNT Investor Presentation
17/11/21PRICE SENSITIVE download Created with Sketch. 2.22MB
SNT Placement
17/11/21PRICE SENSITIVE download Created with Sketch. 152.6KB
SNT Trading Halt
15/11/21PRICE SENSITIVE download Created with Sketch. 228.42KB
SNT FDA Clears PXS Cancer Drug for Phase 2 Liver Cancer Study
09/11/21PRICE SENSITIVE download Created with Sketch. 118.69KB
SNT Quarterly Activities Report
28/10/21PRICE SENSITIVE download Created with Sketch. 514.55KB
SNT Appendix 4C Cash Flow Report
28/10/21PRICE SENSITIVE download Created with Sketch. 193.16KB
SNT PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial
13/10/21PRICE SENSITIVE download Created with Sketch. 116.37KB
SNT PXS Cleared to Progress to Phase 2 Bone Marrow Cancer Trial
05/10/21PRICE SENSITIVE download Created with Sketch. 165.64KB
SNT Pharmaxis Treatment to Prevent Wound and Burns Scars Clears
31/08/21PRICE SENSITIVE download Created with Sketch. 133.42KB
SNT PXS Grants Exclusive Option to Develop High Payload Inhaler
17/08/21PRICE SENSITIVE download Created with Sketch. 169.14KB
SNT Preliminary Final Report
12/08/21PRICE SENSITIVE download Created with Sketch. 945.3KB
SNT PXS Drug Decreases Tumour Burden in Liver Cancer Model
05/08/21PRICE SENSITIVE download Created with Sketch. 132.32KB
SNT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/21PRICE SENSITIVE download Created with Sketch. 1.13MB
SNT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/21PRICE SENSITIVE download Created with Sketch. 180KB
SNT PXS Sells Australian Distribution Rights for A$2m
01/07/21PRICE SENSITIVE download Created with Sketch. 146.07KB
SNT BTC: Exclusive distribution rights for Bronchitol & Aridol
30/06/21PRICE SENSITIVE download Created with Sketch. 118.62KB
SNT PXS Announces First Results in Bone Marrow Cancer Trial
29/06/21PRICE SENSITIVE download Created with Sketch. 118.64KB
SNT Quarterly Activity Report
30/04/21PRICE SENSITIVE download Created with Sketch. 498KB
SNT Appendix 4C - quarterly
30/04/21PRICE SENSITIVE download Created with Sketch. 179.97KB
SNT Sale of Russian Distribution Rights
14/04/21PRICE SENSITIVE download Created with Sketch. 144.32KB
SNT Investor Presentation Capital Raising and Growth Outlook
14/04/21PRICE SENSITIVE download Created with Sketch. 2.45MB
SNT Placement
14/04/21PRICE SENSITIVE download Created with Sketch. 146.13KB
SNT Trading Halt
13/04/21PRICE SENSITIVE download Created with Sketch. 218.32KB
SNT First Patient Enrolled - Clinical Trial for Cancer Treatment
22/02/21PRICE SENSITIVE download Created with Sketch. 132.47KB
SNT Half Yearly Report and Accounts
10/02/21PRICE SENSITIVE download Created with Sketch. 430.36KB
SNT Pharmaxis Exports CF Drug to US - US$3 Million Milestone
09/02/21PRICE SENSITIVE download Created with Sketch. 101.56KB
SNT Appendix 4C - quarterly
29/01/21PRICE SENSITIVE download Created with Sketch. 180.59KB
SNT Quarterly Activity Report - December 2020
29/01/21PRICE SENSITIVE download Created with Sketch. 488.55KB
SNT Pharmaxis Receives US$7m milestone from Chiesi
29/12/20PRICE SENSITIVE download Created with Sketch. 96.51KB
SNT Pharmaxis Prioritises Clinical Program on Myelofibrosis
02/11/20PRICE SENSITIVE download Created with Sketch. 136.14KB
SNT FDA Approves Bronchitol for US Market
02/11/20PRICE SENSITIVE download Created with Sketch. 133.59KB
SNT Appendix 4C - quarterly
30/10/20PRICE SENSITIVE download Created with Sketch. 181.37KB
SNT September Quarter 2020 Activity Report
30/10/20PRICE SENSITIVE download Created with Sketch. 364.14KB
SNT Boehringer Ingelheim discontinues development of BI 1467335
07/09/20PRICE SENSITIVE download Created with Sketch. 684.06KB
SNT Pharmaxis Awarded $1M Australian Government Grant
03/09/20PRICE SENSITIVE download Created with Sketch. 123.9KB
SNT FDA Gives Green Light to Start Myelofibrosis Phase 2 Study
19/08/20PRICE SENSITIVE download Created with Sketch. 91.4KB
SNT Preliminary Final Report
13/08/20PRICE SENSITIVE download Created with Sketch. 934.75KB
SNT US$7 million Bronchitol Launch Milestone Brought Forward
05/08/20PRICE SENSITIVE download Created with Sketch. 101.07KB
SNT Fourth Quarter Activity Report
31/07/20PRICE SENSITIVE download Created with Sketch. 385.4KB
SNT Appendix 4C - quarterly
31/07/20PRICE SENSITIVE download Created with Sketch. 173.02KB
SNT Appendix 4C - quarterly
30/04/20PRICE SENSITIVE download Created with Sketch. 88.08KB
SNT Pharmaxis Quarterly Shareholder Update - March 2020
30/04/20PRICE SENSITIVE download Created with Sketch. 392.68KB
SNT PXS Cancer Drug Ready to Commence Phase 2 Studies Q4 2020
28/04/20PRICE SENSITIVE download Created with Sketch. 145.17KB
SNT Half Yearly Report and Accounts
13/02/20PRICE SENSITIVE download Created with Sketch. 251.24KB
SNT Appendix 4C - quarterly
31/01/20PRICE SENSITIVE download Created with Sketch. 121.39KB
SNT Quarterly Shareholder Update - December 2019
31/01/20PRICE SENSITIVE download Created with Sketch. 372.47KB
(20min delay)
Last
4.2¢
Change
-0.003(6.67%)
Mkt cap ! $57.67M
Open High Low Value Volume
4.4¢ 4.5¢ 4.2¢ $37.11K 834.3K

Buyers (Bids)

No. Vol. Price($)
3 244513 4.2¢
 

Sellers (Offers)

Price($) Vol. No.
4.5¢ 220000 1
View Market Depth
Last trade - 16.10pm 05/11/2024 (20 minute delay) ?
Last
4.3¢
  Change
-0.003 ( 0.23 %)
Open High Low Volume
4.6¢ 4.6¢ 4.2¢ 273190
Last updated 15.59pm 05/11/2024 ?
SNT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.